These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1254 related articles for article (PubMed ID: 18268277)

  • 1. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
    Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
    Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma.
    Friedberg JW
    Haematologica; 2008 Mar; 93(3):336-8. PubMed ID: 18310538
    [No Abstract]   [Full Text] [Related]  

  • 3. Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study.
    Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Gobbi PG; Angrilli F; Brugiatelli M; Musto P; Federico M
    Haematologica; 2008 Sep; 93(9):1335-42. PubMed ID: 18698083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
    Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of second solid cancer in patients after treatment of Hodgkin's disease.
    Glanzmann C; Veraguth A; Lütolf UM
    Strahlenther Onkol; 1994 Mar; 170(3):140-6. PubMed ID: 8160093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
    Morales MD; González FA; Villegas A; del Potro E; Díaz Mediavilla J; Martínez R; Alvarez A; Colomé JA
    Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation.
    Del Cañizo Mf; Amigo Mf; Hernández JM; Sanz G; Núñez R; Carreras E; Alegre A; Cuesta B; Mataix R
    Haematologica; 2000 Apr; 85(4):403-9. PubMed ID: 10756367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer and other second neoplasms after childhood Hodgkin's disease.
    Bhatia S; Robison LL; Oberlin O; Greenberg M; Bunin G; Fossati-Bellani F; Meadows AT
    N Engl J Med; 1996 Mar; 334(12):745-51. PubMed ID: 8592547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
    Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
    Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
    Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.
    Brown JR; Yeckes H; Friedberg JW; Neuberg D; Kim H; Nadler LM; Freedman AS
    J Clin Oncol; 2005 Apr; 23(10):2208-14. PubMed ID: 15753460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.
    Moser EC; Noordijk EM; van Leeuwen FE; Baars JW; Thomas J; Carde P; Meerwaldt JH; van Glabbeke M; Kluin-Nelemans HC
    Haematologica; 2006 Nov; 91(11):1481-8. PubMed ID: 17043014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma.
    Howe R; Micallef IN; Inwards DJ; Ansell SM; Dewald GW; Dispenzieri A; Gastineau DA; Gertz MA; Geyer SM; Hanson CA; Lacy MQ; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2003 Aug; 32(3):317-24. PubMed ID: 12858205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
    J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes.
    De Bruin ML; Sparidans J; van't Veer MB; Noordijk EM; Louwman MW; Zijlstra JM; van den Berg H; Russell NS; Broeks A; Baaijens MH; Aleman BM; van Leeuwen FE
    J Clin Oncol; 2009 Sep; 27(26):4239-46. PubMed ID: 19667275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of autologous stem cell transplantation in first remission on outcome.
    Fanin R; Sperotto A; Ruiz De Elvira C; Zaja F; Stocchi R; Geromin A; Cerno M; Patriarca F; Fanni Canelles M; Damiani D; Baccarani M
    Haematologica; 2000 Sep; 85(9):943-51. PubMed ID: 10980633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis.
    Forrest DL; Nevill TJ; Naiman SC; Le A; Brockington DA; Barnett MJ; Lavoie JC; Nantel SH; Song KW; Shepherd JD; Sutherland HJ; Toze CL; Davis JH; Hogge DE
    Bone Marrow Transplant; 2003 Nov; 32(9):915-23. PubMed ID: 14561993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies.
    Park S; Brice P; Noguerra ME; Simon D; Rousselot P; Kerneis Y; Morel P; Marolleau JP; Gisselbrecht C
    Bone Marrow Transplant; 2000 Aug; 26(3):321-6. PubMed ID: 10967573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre-transplant therapy.
    Laurenti L; Tarnani M; Chiusolo P; La Torre G; Garzia M; Zollino M; Zini G; Balducci M; Leone G; Sica S
    Clin Transplant; 2008; 22(2):191-9. PubMed ID: 18339139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.